Volume contents

Vol. 3, No. 1

Special issue: **Site-specific delivery systems for biotherapeutics**
Guest editor: **Peter W. Taylor**

Rationale for targeted drug delivery
P.W. Taylor & C. Howes 1
Pharmacokinetic requirements for successful site-directed targeting of drugs
C. McMartin 9
Liposomes and biotherapeutics
G. Storm, H.P. Wilms & D.J.A. Crommelin 25
Chimeric antibody: Potential applications for drug delivery and immunotherapy
S.-U. Sin 43
Liposomal delivery of biological response modifiers to macrophages
C.C. Pak & I.J. Fidler 55
Immunotoxins
O.W. Press 65
Clinical experience of targeted therapy
H.-G. Eichler 77
Delivery systems for gene therapy
G.Y. Wu & C.H. Wu 87
Patents in Biotherapy 97
Instructions to authors 101

Vol. 3, No. 2

Special issue: **Tumor necrosis factor**
Guest editor: **Bharat B. Aggarwal**

Introduction to TNF and related lymphokines
G.E. Gifford & D.H. Duckworth 103
Structure of tumor necrosis factor and its receptor
B.B. Aggarwal 113
Antiproliferative and proliferative effects of TNF on normal and tumor cells
K. Haranaka 121
Immunomodulatory effect of tumor necrosis factor
B. Bonavida 127
The role of TNF in diverse pathologic processes
S.L. Kunkel, R.M. Strieter, S.W. Chensue, D.A. Campbell & D.G. Remick 135
The metabolic effects of tumor necrosis factor and other cytokines
C. Grunfeld & K.R. Feingold 143
A tumor necrosis factor binding protein (TNF-BP)-physiological antagonist of TNF
I. Olsson, U. Gullberg, M. Lantz & C. Peetre 159

Evaluation of TNF as antiviral, antibacterial and antiparasitic agent
G.A.W. Rook, J. Taverne & J.H.L. Playfair 167
Clinical studies with TNF
T. Taguchi & Y. Sohmura 177
Patents in Biotherapy 187
Instructions to authors 191

Vol. 3, No. 3

Search for immunobiological parameters predictive of clinical effects of OK-432 in patients with malignant ascites
M. Kataoka, S. Hashimoto, M. Nanjo, M. Saito, Y. Sugawara, T. Yoshida, T. Kamano, M. Urabe, K. Nishimura & N. Sakakibara 193
Augmentation of antitumor effect on syngeneic murine solid tumors by an interleukin 2 slow delivery system, the IL-2 mini-pellet
T. Fujiwara, K. Sakagami, J. Matsuoka, S. Shiozaki, K. Fujioka, Y. Takada, S. Uchida, T. Onoda & K. Orita 203
Inhibition of growth of rat hepatoma by local injection of liposomes containing recombinant interleukin-2: Antitumor effect of IL-2 liposome
H. Konno, A. Yamashita, T. Tadakuma & S. Sakaguchi 211
In vivo distribution and cytokine gene expression by enriched mouse LAK effector cells
H. Futami, A.M. Pilaro, M.E. Gruys, T.C. Back, H.A. Young & R.H. Wiltrout 219
In vitro modulation of canine polymorphonuclear leukocyte function by granulocyte-macrophage colony stimulating factor
M.M. D'Alesandro, D.F. Gruber, K.P. O'Halloran & T.J. MacVittie 233
The effect of photosensitive dye Platonin on juvenile rheumatoid arthritis
F. Motoyoshi, N. Kondo, H. Ono & T. Orii 241
A regimen of surgical adjuvant immunotherapy for cancer with interleukin 2 and lymphokine-activated killer cells: Basis, clinical toxicity, and immunomodulatory effects
T. Yano, T. Ishida, I. Yoshino, M. Murata, K. Yasumoto, G. Kimura, K. Nomoto & K. Sugimachi 245
BLT-esterase activity following *in vitro* and *in vivo* activation of human lymphocytes with interleukin-2: *In vivo* IL-2 induces BLT-esterase
A. Cannon, J.A. Hank & P.M. Sondel 253
A case report of a 9-year old boy with polyarteritis nodosa in which a combination therapy of corticosteroids and a photosensitive dye Platonin was effective
N. Kondo, F. Motoyoshi, T. Ozawa & T. Orii 261
The synergistic effects of gamma interferon and clofazimine on phagocyte function: Restoration of inhibition due to a 25 kilodalton fraction from *Mycobacterium tuberculosis*
R.B. Parak & A.A. Wadee 265
Protective effect of carboxyethylgermanium sesquioxide (Ge-132) on superoxide generation by ^{60}Co-irradiated leukocytes
L. Prónai & S. Arimori 273
Patents in Biotherapy 281
Instructions to authors 284

Vol. 3, No. 4

Alternating immunochemotherapy of advanced gastric carcinoma: A randomized comparison of carbazilquinone and PSK to carbazilquinone in patients with curative gastric resection
T. Kondo, J. Sakamoto & H. Nakazato 287

Clinical effect of recombinant human granulocyte colony-stimulating factor (rhG-CSF) on various types of neutropenia including cyclic neutropenia
K. Hirashima, Y. Yoshida, S. Asano, F. Takaku, M. Omine, S. Furusawa, Tsukasa Abe, Tatsuo Abe, H. Dohy, M. Tajiri & S. Eto 297

Clinical trial of natural human lymphocyte-derived interleukin 2 in cancer patients: Effects on cytokine production and suppressor cell status
G. Pawelec, H.-J. Lenz, E. Schneider, H.-J. Bühring, A. Rehbein, P. Baumgärtner & G. Ehninger 309

Transfer of long-lasting tumor immunity by immune T cells from MHC congenic mice: Migration, survival and tumor-protectivity of cytotoxic donor cells
U. Zangemeister-Wittke & V. Schirrmacher 319

Antitumor action of an acidic glycoprotein (SAGP) from *Streptococcus pyogenes* in mice
J. Yoshida, S. Takamura & S. Suzuki 331

In vivo effects of human recombinant tumor necrosis factor alone and in combination with other biological response modifiers on human digestive organ cancer xenografts transplanted in nude mice
Y. Nio, T. Shiraishi, M. Tsubono, H. Morimoto, C.-C. Tseng, K. Kawabata, Y. Masai, T. Tun, M. Fukumoto & T. Tobe 337

Intrapleural application of recombinant interleukin-2 in patients with malignant pleurisy due to lung cancer: A multi-institutional cooperative study
K. Yasumoto & T. Ogura 345

Growth inhibitory effect of bestatin on choriocarcinoma cell lines *in vitro*
K. Ino, S. Goto, A. Kosaki, S. Nomura, E. Asada, T. Misawa, Y. Furuhashi, S. Mizutani & Y. Tomoda 351

The augmentative effect of a protein-bound polysaccharide (PSK) on tumoricidal activity of the soluble factor produced by a streptococcal preparation (OK-432)-activated macrophages
N. Baba, H. Kawami, Y. Sato, T. Takayama & T. Toge 359

BG-104 enhances the decreased plasma superoxide scavenging activity in patients with Behçet's disease, Sjögren's syndrome or hematological malignancy
L. Prónai & S. Arimori 365

A possible clinical application of multicytokine-producing cytotoxic mononuclear cell (MCCM) therapy
M. Katano, E. Kubota, H. Yamamoto, M. Nakamura, T. Matsuo, T. Hisatsugu, T. Katsuki, H. Koga, K. Ikezaki, K. Tabuchi, F. Nagumo & J. Tadano 373

Patents in Biotherapy 381

Instructions to authors 383

List of contributors 385